FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952462017> ?p ?o ?g. }

• W2952462017 endingPage "4515" @default.
• W2952462017 startingPage "4503" @default.
• W2952462017 abstract "Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFRL858R/T790M, mutation Guoqun Wang,1 Jiaojiao Zhao,2 Meiling Zhang,1 Qian Wang,1 Bo Chen,3 Yayi Hou,2,4 Kaihua Lu11Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, People’s Republic of China; 2The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing 210093, People’s Republic of China; 3Institute of Materials Science and Devices, Suzhou University of Science and Technology, Suzhou 215009, People’s Republic of China; 4Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, Nanjing 210093, People’s Republic of ChinaPurpose: Drug resistance is a major challenge for epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) treatment of lung cancer. Ferumoxytol (FMT) drives macrophage (MΦ) transformation towards a M1-like phenotype and thereby inhibits tumor growth. CpG oligodeoxynucleotide 2395 (CpG), a toll-like receptor 9 (TLR9) agonist, is an effective therapeutic agent to induce anticancer immune responses. Herein, the effect of co-administered FMT and CpG on MΦ activation for treating non-small cell lung cancer (NSCLC) was explored.Methods: The mRNA expression levels of M1-like genes in RAW 264.7 MΦ cells stimulated by FMT, CpG and FMT and CpG (FMT/CpG) were evaluated by quantitative reverse transcription PCR (qRT-PCR). Then, the effects of FMT/CpG-pretreated MΦ supernatant on apoptosis and proliferation of H1975 cells were detected by flow cytometry, and the expression of EGFR and its downstream signaling pathway in H1975 cells were explored by western blotting. Finally, a H1975 cell xenograft mouse model was used to study the anti-tumor effect of the combination of FMT and CpG in vivo.Results: FMT and CpG synergistically enhanced M1-like gene expression in MΦ, including tumor necrosis factor-α, interleukin (IL)-12, IL-1α, IL-1β, IL-6 and inducible nitric oxide synthase (iNOS). FMT/CpG-pretreated MΦ supernatant inhibited proliferation and induced apoptosis of H1975 cells, accompanied by down-regulation of cell cycle-associated proteins and up-regulation of apoptosis-related proteins. Further studies indicated that the FMT/CpG-pretreated MΦ supernatant suppressed p-EGFR and its downstream AKT/mammalian target of rapamycin signaling pathway in H1975 cells. Furthermore, FMT/CpG suppressed tumor growth in mice accompanied by a decline in the EGFR-positive tumor cell fraction and increased M1 phenotype macrophage infiltration.Conclusion: FMT acted synergistically with CpG to activate MΦ for suppressed proliferation and promoted apoptosis of NSCLC cells via EGFR signaling. Thus, combining FMT and CpG is an effective strategy for the treatment of NSCLC with EGFRL858R/T790M, mutation.Keywords: ferumoxytol, CpG oligodeoxynucleotide, macrophages, non-small cell lung cancer, epidermal growth factor receptor" @default.
• W2952462017 created "2019-06-27" @default.
• W2952462017 creator A5014944871 @default.
• W2952462017 creator A5046225712 @default.
• W2952462017 creator A5048874956 @default.
• W2952462017 creator A5051884399 @default.
• W2952462017 creator A5065754983 @default.
• W2952462017 creator A5067483347 @default.
• W2952462017 creator A5072790694 @default.
• W2952462017 date "2019-06-01" @default.
• W2952462017 modified "2023-10-16" @default.
• W2952462017 title "<p>Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR^L858R/T790M mutation</p>" @default.
• W2952462017 cites W1546072594 @default.
• W2952462017 cites W1546552389 @default.
• W2952462017 cites W1636849021 @default.
• W2952462017 cites W1880795594 @default.
• W2952462017 cites W1974023961 @default.
• W2952462017 cites W1987431901 @default.
• W2952462017 cites W1987964666 @default.
• W2952462017 cites W1992848513 @default.
• W2952462017 cites W1998206686 @default.
• W2952462017 cites W2039469453 @default.
• W2952462017 cites W2058935900 @default.
• W2952462017 cites W2072114397 @default.
• W2952462017 cites W2087572503 @default.
• W2952462017 cites W2088540000 @default.
• W2952462017 cites W2095243943 @default.
• W2952462017 cites W2103615468 @default.
• W2952462017 cites W2105357534 @default.
• W2952462017 cites W2121689078 @default.
• W2952462017 cites W2137778691 @default.
• W2952462017 cites W2156953670 @default.
• W2952462017 cites W2159423482 @default.
• W2952462017 cites W2165181124 @default.
• W2952462017 cites W2170612601 @default.
• W2952462017 cites W2173603370 @default.
• W2952462017 cites W2266456418 @default.
• W2952462017 cites W2415283090 @default.
• W2952462017 cites W2493769811 @default.
• W2952462017 cites W2515707341 @default.
• W2952462017 cites W2560717039 @default.
• W2952462017 cites W2761796554 @default.
• W2952462017 cites W2762122558 @default.
• W2952462017 cites W2767749438 @default.
• W2952462017 cites W2770979668 @default.
• W2952462017 cites W2772593880 @default.
• W2952462017 cites W2788915957 @default.
• W2952462017 cites W2790882351 @default.
• W2952462017 cites W2795247507 @default.
• W2952462017 cites W2800676430 @default.
• W2952462017 cites W2801531086 @default.
• W2952462017 cites W2805533573 @default.
• W2952462017 cites W2807131271 @default.
• W2952462017 cites W2809991672 @default.
• W2952462017 cites W2885358256 @default.
• W2952462017 cites W2886911223 @default.
• W2952462017 cites W2887100062 @default.
• W2952462017 cites W2887416920 @default.
• W2952462017 cites W2888297236 @default.
• W2952462017 cites W2889646458 @default.
• W2952462017 cites W2890107533 @default.
• W2952462017 cites W2890117219 @default.
• W2952462017 cites W2891007000 @default.
• W2952462017 cites W2891059887 @default.
• W2952462017 cites W2893960509 @default.
• W2952462017 cites W2894717949 @default.
• W2952462017 cites W2902852740 @default.
• W2952462017 cites W2911188335 @default.
• W2952462017 doi "https://doi.org/10.2147/ijn.s193583" @default.
• W2952462017 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6599896" @default.
• W2952462017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31417255" @default.
• W2952462017 hasPublicationYear "2019" @default.
• W2952462017 type Work @default.
• W2952462017 sameAs 2952462017 @default.
• W2952462017 citedByCount "13" @default.
• W2952462017 countsByYear W29524620172019 @default.
• W2952462017 countsByYear W29524620172020 @default.
• W2952462017 countsByYear W29524620172021 @default.
• W2952462017 countsByYear W29524620172022 @default.
• W2952462017 countsByYear W29524620172023 @default.
• W2952462017 crossrefType "journal-article" @default.
• W2952462017 hasAuthorship W2952462017A5014944871 @default.
• W2952462017 hasAuthorship W2952462017A5046225712 @default.
• W2952462017 hasAuthorship W2952462017A5048874956 @default.
• W2952462017 hasAuthorship W2952462017A5051884399 @default.
• W2952462017 hasAuthorship W2952462017A5065754983 @default.
• W2952462017 hasAuthorship W2952462017A5067483347 @default.
• W2952462017 hasAuthorship W2952462017A5072790694 @default.
• W2952462017 hasBestOaLocation W29524620171 @default.
• W2952462017 hasConcept C104317684 @default.
• W2952462017 hasConcept C121608353 @default.
• W2952462017 hasConcept C126322002 @default.
• W2952462017 hasConcept C140173407 @default.
• W2952462017 hasConcept C150194340 @default.
• W2952462017 hasConcept C153911025 @default.
• W2952462017 hasConcept C185592680 @default.
• W2952462017 hasConcept C190727270 @default.
• W2952462017 hasConcept C22801619 @default.

• next